Frzb, a Secreted Wnt Antagonist, Decreases Growth and Invasiveness of Fibrosarcoma Cells Associated with Inhibition of Met Signaling

Overview

Journal Cancer Res

Specialty Oncology

Date 2008 May 3

PMID 18451162

Citations 43

Authors

Yi Guo

Jun Xie

Elyssa Rubin

Ya-Xiong Tang

Fritz Lin

Xiaolin Zi

Bang H Hoang

Affiliations

Soon will be listed here.

Abstract

Soft tissue sarcomas (STS) have a strong propensity for aggressive growth and metastasis. We showed that the secreted Wnt antagonist Frzb exhibited potent antitumor activity against prostate cancer, an epithelial type of malignancy. In this study, we further showed the antitumor efficacy of Frzb in STS, a mesenchymal group of cancer. Frzb transfection of HT1080 (fibrosarcoma) and SW872 (liposarcoma) cell lines and their conditioned media resulted in a significant reduction in cellular invasion, motility, and colony formation in soft agar compared with vector control-transfected cells. In a xenograft mouse model, Frzb dramatically suppressed tumor growth of HT1080 cells in nude mice. In a tail-vein injection metastatic model, Frzb-transfected HT1080 cells formed fewer and smaller lung nodules than vector control cells. In addition, we identified new mechanisms for Frzb antitumor activities. Frzb reduced c-Met expression and inhibited Met-mediated signaling, associated with up-regulation of epithelial markers (i.e., keratins 8 and 18) and down-regulation of mesenchymal markers (i.e., vimentin, N-cadherin, fibronectin, Slug, and Twist). Similar to Frzb, silencing of c-Met by short hairpin RNA or using a dominant-negative LRP5 receptor also suppressed Met signaling, leading to reduced cellular motility, invasion, and in vivo tumor growth. Given recent studies indicating an important role of c-Met in sarcoma development and progression, our data showed that Frzb expression was significantly inversely correlated with Met expression in both STS cell lines and tissues. These results suggested the usefulness of Frzb in modulating Met signaling as a new treatment strategy for STS.

Citing Articles

Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities.

Liu H, Wang X, Liu L, Yan B, Qiu F, Zhou B Front Oncol. 2024; 14:1484027.

PMID: 39723387 PMC: 11668776. DOI: 10.3389/fonc.2024.1484027.

FRZB: a potential prognostic marker for head and neck squamous cell carcinoma.

Li Y, Gu F, Huang X, Huang W, Xiang J, Yue J Braz J Med Biol Res. 2024; 57:e13368.

PMID: 38775547 PMC: 11101165. DOI: 10.1590/1414-431X2024e13368.

FRZB affects aureus‑induced osteomyelitis in human bone marrow derived stem cells by regulating the Wnt/β‑catenin signaling pathway.

Li X, Pang W, Fan H, Wang H, Zhang L Exp Ther Med. 2023; 26(5):531.

PMID: 37869648 PMC: 10587868. DOI: 10.3892/etm.2023.12230.

hapln1a cells guide coronary growth during heart morphogenesis and regeneration.

Sun J, Peterson E, Chen X, Wang J Nat Commun. 2023; 14(1):3505.

PMID: 37311876 PMC: 10264374. DOI: 10.1038/s41467-023-39323-6.

EZH2 activates Wnt/β-catenin signaling in human uterine fibroids, which is inhibited by the natural compound methyl jasmonate.

Ali M, Stone D, Laknaur A, Yang Q, Al-Hendy A F S Sci. 2023; 4(3):239-256.

PMID: 37182601 PMC: 10527015. DOI: 10.1016/j.xfss.2023.05.003.

References

Mohinta S, Wu H, Chaurasia P, Watabe K . Wnt pathway and breast cancer. Front Biosci. 2007; 12:4020-33. DOI: 10.2741/2368. View

Taniwaki K, Fukamachi H, Komori K, Ohtake Y, Nonaka T, Sakamoto T . Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res. 2007; 67(9):4311-9. DOI: 10.1158/0008-5472.CAN-06-4761. View

Tsai C, Tsai C, Tse K, Chang H, Chang Y . The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A. 2002; 99(15):10084-9. PMC: 126628. DOI: 10.1073/pnas.152059399. View

Sievers S, Fritzsch C, Lehnhardt M, Zahn S, Kutzner N, Kuhnen C . Hypermethylation of the APC promoter but lack of APC mutations in myxoid/round-cell liposarcoma. Int J Cancer. 2006; 119(10):2347-52. DOI: 10.1002/ijc.22117. View

Zi X, Guo Y, Simoneau A, Hope C, Xie J, Holcombe R . Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res. 2005; 65(21):9762-70. DOI: 10.1158/0008-5472.CAN-05-0103. View

Luu H, Zhang R, Haydon R, Rayburn E, Kang Q, Si W . Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets. 2004; 4(8):653-71. DOI: 10.2174/1568009043332709. View

Mikami I, You L, He B, Xu Z, Batra S, Lee A . Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC Cancer. 2005; 5:53. PMC: 1164405. DOI: 10.1186/1471-2407-5-53. View

Yuan J, Dutton C, Scully S . RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res. 2005; 23(6):1467-74. DOI: 10.1016/j.orthres.2005.04.004.1100230633. View

Hoang B, Kubo T, Healey J, Yang R, Nathan S, Kolb E . Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res. 2004; 64(8):2734-9. DOI: 10.1158/0008-5472.can-03-1952. View

10.

Marchenko G, Marchenko N, Leng J, Strongin A . Promoter characterization of the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 implies specific expression of the gene in cancer cells of epithelial origin. Biochem J. 2002; 363(Pt 2):253-62. PMC: 1222473. DOI: 10.1042/0264-6021:3630253. View

11.

Fukuda T, Ichimura E, Shinozaki T, Sano T, Kashiwabara K, Oyama T . Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int. 1998; 48(10):757-62. DOI: 10.1111/j.1440-1827.1998.tb03834.x. View

12.

Saito T, Oda Y, Sakamoto A, Kawaguchi K, Tanaka K, Matsuda S . APC mutations in synovial sarcoma. J Pathol. 2002; 196(4):445-9. DOI: 10.1002/path.1066. View

13.

DeAlmeida V, Miao L, Ernst J, Koeppen H, Polakis P, Rubinfeld B . The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res. 2007; 67(11):5371-9. DOI: 10.1158/0008-5472.CAN-07-0266. View

14.

Nagayama S, Fukukawa C, Katagiri T, Okamoto T, Aoyama T, Oyaizu N . Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene. 2005; 24(41):6201-12. DOI: 10.1038/sj.onc.1208780. View

15.

Ponzetto C, Giordano S, Peverali F, Della Valle G, Abate M, Vaula G . c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene. 1991; 6(4):553-9. View

16.

Mandal D, Srivastava A, Mahlum E, Desai D, Maran A, Yaszemski M . Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene. 2006; 386(1-2):131-8. DOI: 10.1016/j.gene.2006.08.030. View

17.

Hoang B, Moos Jr M, Vukicevic S, Luyten F . Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem. 1996; 271(42):26131-7. DOI: 10.1074/jbc.271.42.26131. View

18.

Tejpar S, Nollet F, Li C, Wunder J, Michils G, Dal Cin P . Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999; 18(47):6615-20. DOI: 10.1038/sj.onc.1203041. View

19.

Ferracini R, Olivero M, Di Renzo M, Martano M, De Giovanni C, Nanni P . Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene. 1996; 12(8):1697-705. View

20.

Coussens L, Fingleton B, Matrisian L . Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295(5564):2387-92. DOI: 10.1126/science.1067100. View